About Viridian Therapeutics, Inc.
https://www.viridiantherapeutics.comViridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
CEO
Stephen F. Mahoney MBA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-13 | Reverse | 1:15 |
| 2016-11-07 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 131
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Needham
Buy
BTIG
Buy
Goldman Sachs
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:12.25M
Value:$413.78M
BLACKROCK, INC.
Shares:5.43M
Value:$183.38M
DEEP TRACK CAPITAL, LP
Shares:5.38M
Value:$181.75M
Summary
Showing Top 3 of 187
About Viridian Therapeutics, Inc.
https://www.viridiantherapeutics.comViridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $70.57M ▲ | $110.58M ▲ | $-34.6M ▲ | -49.03% ▲ | $-0.34 ▲ | $-33.93M ▲ |
| Q2-2025 | $75K ▲ | $106.84M ▲ | $-100.73M ▼ | -134.31K% ▼ | $-1 ▼ | $-100.11M ▼ |
| Q1-2025 | $72K | $93.94M ▲ | $-86.91M ▼ | -120.71K% ▼ | $-0.87 ▼ | $-86.21M ▼ |
| Q4-2024 | $72K ▼ | $87.54M ▲ | $-79.72M ▼ | -110.73K% ▼ | $-0.81 ▲ | $-78.74M ▼ |
| Q3-2024 | $86K | $83.57M | $-76.69M | -89.17K% | $-1.15 | $-75.56M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $490.9M ▼ | $577.14M ▼ | $74.17M ▲ | $502.97M ▼ |
| Q2-2025 | $563.36M ▼ | $582.32M ▼ | $67.16M ▲ | $515.17M ▼ |
| Q1-2025 | $636.63M ▼ | $660.98M ▼ | $56.51M ▼ | $604.47M ▼ |
| Q4-2024 | $717.58M ▼ | $742.4M ▼ | $70.76M ▲ | $671.64M ▼ |
| Q3-2024 | $753.24M | $771.9M | $64.4M | $707.5M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.6M ▲ | $-84.61M ▼ | $126.08M ▲ | $10.86M ▲ | $52.32M ▲ | $-84.74M ▼ |
| Q2-2025 | $-100.73M ▼ | $-75.37M ▲ | $75.72M ▼ | $764K ▼ | $1.11M ▼ | $-75.42M ▲ |
| Q1-2025 | $-86.91M ▼ | $-92.65M ▼ | $100.06M ▲ | $9.21M ▼ | $16.62M ▲ | $-92.74M ▼ |
| Q4-2024 | $-79.72M ▼ | $-73.33M ▼ | $-62.91M ▲ | $35.52M ▼ | $-100.72M ▼ | $-73.45M ▼ |
| Q3-2024 | $-76.69M | $-67.71M | $-84.67M | $245.02M | $92.65M | $-68M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Collaboration Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License | $0 ▲ | $0 ▲ | $0 ▲ | $70.00M ▲ |
CEO
Stephen F. Mahoney MBA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-13 | Reverse | 1:15 |
| 2016-11-07 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 131
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Needham
Buy
BTIG
Buy
Goldman Sachs
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:12.25M
Value:$413.78M
BLACKROCK, INC.
Shares:5.43M
Value:$183.38M
DEEP TRACK CAPITAL, LP
Shares:5.38M
Value:$181.75M
Summary
Showing Top 3 of 187